By using different combinations of such mAbs with known epitopes, we can enhance our knowledge of the plasma-tau profile and develop a better understanding of which fragments are best quantified for the greatest discrimination between healthy people and those in the early stages of developing AD. Here, MAPT is linked to Alzheimer disease.